China
Africa
Explore chapters and articles related to this topic
Paper 3
Published in Amanda Rabone, Benedict Thomson, Nicky Dineen, Vincent Helyar, Aidan Shaw, The Final FRCR, 2020
Amanda Rabone, Benedict Thomson, Nicky Dineen, Vincent Helyar, Aidan Shaw
Intraductal papillary mucinous neoplasms are thin-walled cysts which have a connection with the pancreatic duct. They can be split into branch or main duct lesions. Branch duct lesions often resemble a bunch of grapes and the main duct subtype causes pancreatic duct dilatation. Neither usually contain calcification.
Multifocal Branch Duct Intraductal Papillary Mucinous Neoplasm with 3 cm Lesion in Head of Pancreas
Published in Savio George Barreto, Shailesh V. Shrikhande, Dilemmas in Abdominal Surgery, 2020
Atsushi Oba, Robert J. Torphy, Richard D. Schulick, Marco Del Chiaro
Intraductal papillary mucinous neoplasm is a type of pancreatic cystic neoplasm which is increasingly being identified on cross-sectional imaging. Of all the pancreatic cystic neoplasms, the ones with malignant potential, namely main duct intraductal papillary mucinous neoplasm, branch duct type intraductal papillary mucinous neoplasm, and mucinous cystic neoplasm should be clearly identified [1].
McCune–Albright Syndrome
Published in Dongyou Liu, Tumors and Cancers, 2017
Hepatitis and hepatic adenomas may occur in infants. Gastroesophageal reflux and gastrointestinal polyps are observed in childhood. Pancreatitis and intraductal papillary mucinous neoplasms are also found. Benign intramuscular myxomas (Mazabraud syndrome) are also found incidentally. Cancers affecting the bone, thyroid, testicles, and breast are observed occasionally.
IPMN of the pancreas – does histological subtyping allow for improved stratification and follow-up?
Published in Scandinavian Journal of Gastroenterology, 2021
Daniel Ansari, Jacob Amini, Maja Edman, Roland Andersson
Intraductal papillary mucinous neoplasms (IPMNs) are mucin-producing cystic lesions that involve the pancreatic ductal system. A subset of IPMNs will progress to invasive carcinoma. IPMNs can be classified based on anatomy as well as histology. IPMNs engaging the main pancreatic duct are termed main duct type, those engaging branch ducts are termed branch duct type, and those communicating with both ducts are termed mixed type. IPMNs that involve the main pancreatic duct have a higher risk of malignancy compared to IPMNs with exclusively branch duct engagement [1]. Histologically, IPMNs are divided into three subtypes: intestinal, gastric, and pancreatobiliary. These subtypes have been suggested to develop via different signaling pathways and appear to have different biological behavior [2].
Diagnostic performance of current guidelines and postoperative outcome following surgical treatment of cystic pancreatic lesions – a 10-year single center experience
Published in Scandinavian Journal of Gastroenterology, 2020
Bojan Kovacevic, Mariana Cordoba Hansen, Thomas Skaarup Kristensen, John Gásdal Karstensen, Pia Klausen, Jan Storkholm, Carsten Palnaes Hansen, Peter Vilmann
We identified 137 patients, three of which did not undergo curative surgery due to metastatic disease. Demographical data and lesion characteristics are presented in Table 1. As for the final diagnosis, 72 lesions (52.6%) were low-grade dysplastic or non-neoplastic, 29 (21.1%) harbored high grade dysplasia, and 36 (26.3%) were malignant. Tumor stage in the malignant group was I in 11 cases, II in 2 cases, III in 20 cases, and IV in the remaining 3 cases. Histological diagnosis revealed an overweight of intraductal papillary mucinous neoplasm [IPMN] (n = 106), followed by serous cystic neoplasm (n = 10), mucinous cystic neoplasm (n = 9), intraductal tubulopapillary neoplasm (n = 2), neuroendocrine tumor (n = 2), and other (n = 8). Grade of dysplasia across different histological types is shown in Figure 1, and the observed prevalence of advanced neoplasia in main-duct and side-branch IPMNs was 57% and 52%, respectively.
Applications of multiple reaction monitoring targeted proteomics assays in human plasma
Published in Expert Review of Molecular Diagnostics, 2019
Georgia Kontostathi, Manousos Makridakis, Jerome Zoidakis, Antonia Vlahou
Kim et al. [57] focused on the diagnosis of Intraductal papillary mucinous neoplasm (IPMN), which is a precursor of PC stages. Plasma samples from 184 patients corresponding to- low and intermediate-grade dysplasia IPMN, high-grade dysplasia IPMN, invasive IPMN, and controls were divided into a training (n = 84) and a test (n = 100) set (Table S1). Initially, 260 targets were selected for evaluation based on the literature and database resources, which after serial filtering based on their detectability and a preliminary quantification experiment, were shortlisted to 22 proteins, subjected to MRM validation in the test set. Based on the latter, 11 proteins were highlighted, of which a 6-protein panel (C5, CPN2, IGFBP2, IGFBP3, LDHB, and PPBP) exhibited a good discriminatory potential between IPMN and controls (training set: AUC = 0.957 – test set: AUC = 0.984). This panel exhibited better performance than the known biomarkers CEA and CA19-9 (training set: AUCCEA = 0.568, AUCCA19-9= 0.628 – test set: AUCCEA = 0.647, AUCCA19-9= 0.551). This study (classified as Tier 2) addressed a significant clinical need (biomarkers for early PC detection), nevertheless, the risk for overfitting is existent and, as also indicated by the authors, results should be validated in a larger independent cohort [57].